Precision Genome Engineering Inc.

Precision Genome Engineering, based in Seattle, WA, is a pioneering company focused on developing curative gene therapies for diseases such as Beta-Thalassemia, Cerebral Adrenoleukodystrophy, and Sickle Cell Disease. With a strong emphasis on diversity, equity, and inclusion, their one-time gene therapy for Sickle Cell Disease has received FDA approval, showcasing their commitment to advancing the field of gene therapy.

Driven by a mission to provide patients and their families with more "bluebird days," Precision Genome Engineering sets the standard for gene therapy with their innovative approach and deep ex-vivo gene therapy data set. Through their proprietary lentiviral vector gene therapies, they aim to deliver functional genes to patients' cells, offering hope for a brighter future in the treatment of genetic diseases.

Generated from the website